sur MAbxience
MAbxience and Sandoz Join Forces to Enhance Global Access to Biosimilars
mAbxience and Sandoz have formed a collaboration to advance a proposed emicizumab biosimilar for hemophilia A treatment. This agreement combines mAbxience's development and manufacturing prowess with Sandoz's vast commercial network. It aims to enhance patient access to quality biologic medicines worldwide.
Under this partnership, mAbxience will develop and produce the biosimilar in Spain and Argentina. Sandoz will commercialize it globally, except in Argentina, Uruguay, and Paraguay. The financial specifics remain undisclosed. The agreement marks a strategic move as biologic medicines face upcoming patent expirations.
The focus is on expanding into the USD 5.7 billion hemophilia A market. This condition is a prevalent genetic disorder causing defective blood clotting. The collaboration underscores mAbxience's leading role in biosimilar innovation and its commitment to addressing unmet medical needs globally.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MAbxience